RxSight, Inc. Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
ALISO VIEJO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) — RxSight, Inc. (“RxSight®”), an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that, in connection with its previously announced public offering of common stock (the “Offering”), the underwriters exercised in full their option to purchase an additional 600,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
What does this mean for RxSight, Inc.?
This full exercise of the underwriters’ option to purchase additional shares is a positive development for RxSight, Inc. It indicates strong demand for the company’s common stock and reflects investor confidence in the company’s vision and potential for growth in the ophthalmic medical device market.
How will this affect individuals?
For individuals, the full exercise of the underwriters’ option to purchase additional shares may present an opportunity for investment in RxSight, Inc. As the company continues to innovate and develop new technologies to improve vision following cataract surgery, investors may see potential for long-term returns on their investment.
How will this impact the world?
RxSight, Inc.’s commitment to improving the vision of patients following cataract surgery has the potential to have a significant impact on the world. By developing advanced ophthalmic medical devices, the company is helping to enhance the quality of life for individuals suffering from cataracts, ultimately contributing to improved global eye health.
Conclusion
The full exercise of the underwriters’ option to purchase additional shares is a positive development for RxSight, Inc. and signifies strong investor interest in the company’s future prospects. This announcement highlights the company’s dedication to improving vision for patients following cataract surgery and underscores its potential for growth and innovation in the ophthalmic medical device market.
